{"created":"2023-06-20T16:46:31.775230+00:00","id":18034,"links":{},"metadata":{"_buckets":{"deposit":"aa5f584f-416b-4a0d-8cc2-1d455311b19b"},"_deposit":{"created_by":29,"id":"18034","owners":[29],"pid":{"revision_id":0,"type":"depid","value":"18034"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00018034","sets":["14:2667:4296"]},"author_link":["30702","30604","30701"],"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"5","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2015)"}]}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：胎児頻脈性不整脈の治療によるDXおよびSTの経胎盤的投与を導入された入院対象患者32例を解析した。臍帯血/母体血の平均薬剤移行率はDX(16例)67.6%、ST(7例)73.9%であった。DX濃度(26例)は推定クレアチニンクリアランス(Ccr)と相関を示さず(P=0.18)、血清クレアチニン(Scr)とは相関傾向（P=0.06）、投与量と相関を示した(P<0.001)。ST濃度(12例)はCcr、Scrと相関を示さず、投与量と相関を示した(P=0.04)。胎児心拍数は薬物療法導入から対数近似的に速やかに低下した。対象症例をさらに集積し、胎児頻脈性不整脈治療の保険診療の承認申請を予定している。\n研究成果の概要（英文）：This study was conducted in 32 hospitalized patients (average age 31.2, average weight 59.0) to investigate pharmacokinetics and pharmacodynamic. The mean cord blood/maternal plasma concentration of DX (16 examples) and ST (7 examples) was 67.6% and 73.9%, respectively.As for the dosage, a correlation was found in both DX plasma concentrations (26 examples) (P<0.001) and ST plasma concentration (12 examples) (P=0.04). There was a correlation tendency between DX plasma concentration and serum creatinine (Scr) (P=0.06), was not a significant correlation between ST plasma concentration and Scr (P=0.18). Furthermore, maternal heart rate related to DX plasma concentration weakly (P=0.09), but did not relate to ST plasma concentration (P=0.51). Treatment of fetus tachycardia made fetal atrial heart rate decreased like log approximation. It is expected to apply for approval of health insurance treatment by analyzing more additional target cases.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究(C);  研究期間：2011～2015;   課題番号：23591607;   研究分野：医療薬剤;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_relation_11":{"attribute_name":"著者 外部リンク","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591607/"}]}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"},{"subitem_text_value":"研究協力者"},{"subitem_text_value":"研究協力者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"KOTAKE, Takeshi"},{"subitem_text_language":"en","subitem_text_value":"KATSURAGI, Shinji"},{"subitem_text_language":"en","subitem_text_value":"IKEDA, Tomoaki"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学薬学部; 教授"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小竹, 武"},{"creatorName":"コタケ, タケシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"桂木, 真司"},{"creatorName":"カツラギ, シンジ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"池田, 智明"},{"creatorName":"イケダ, トモアキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-10-17"}],"displaytype":"detail","filename":"23591607seika.pdf","filesize":[{"value":"322.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"23591607seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/18034/files/23591607seika.pdf"},"version_id":"5986c979-abac-4f28-b58f-0318b4d867a3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"胎児不整脈","subitem_subject_scheme":"Other"},{"subitem_subject":"抗不整脈薬","subitem_subject_scheme":"Other"},{"subitem_subject":"薬物血中濃度","subitem_subject_scheme":"Other"},{"subitem_subject":"経胎盤的胎児治療","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"胎児頻脈性不整脈に対する経胎盤的抗不整脈薬投与の薬物血中濃度による評価","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"胎児頻脈性不整脈に対する経胎盤的抗不整脈薬投与の薬物血中濃度による評価"},{"subitem_title":"Evaluation of Plasma Concentration of the Antiarrhythmic Agent for Treatment of Fetus Tachycardia","subitem_title_language":"en"}]},"item_type_id":"8","owner":"29","path":["4296"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-10-17"},"publish_date":"2016-10-17","publish_status":"0","recid":"18034","relation_version_is_last":true,"title":["胎児頻脈性不整脈に対する経胎盤的抗不整脈薬投与の薬物血中濃度による評価"],"weko_creator_id":"29","weko_shared_id":-1},"updated":"2023-06-20T22:10:14.057062+00:00"}